The news comes weeks after the Hingham, Massachusetts-based company began a limited U.S. commercial launch of Liberty. The FDA in September cleared Liberty, a remotely operated robotic system for peripheral endovascular procedures.
Microbot Medical plans for a full market release of Liberty at the Society of Interventional Radiology (SIR) conference in April 2026. According to the company, the Liberty system offers a way to advance robotics without the constraints of capital equipment or dedicated infrastructure.
“Introducing innovative technologies such as Liberty to our interventional radiology program underscores our priority to remain at the forefront of technological advancement. We anticipate that its single-use, remotely operated design will offer a practical and scalable approach to robotics that supports our operational goals, protects our clinicians and provides access to quality care,” said Dr. J. David Prologo, division director for interventional radiology at Emory University School of Medicine, in a news release.
Microbot Medical CEO Harel Gado described the adoption of Liberty at Emory as a major milestone for the entire surgical robotics space.
“We are establishing a completely new medical robotic category with the adoption of the first FDA-cleared single-use robotic system. This achievement reflects years of dedication and sustained progress by the entire team,” Gadot said.
“Emory University Hospital clinicians and researchers have demonstrated enthusiasm early on about this technology and in providing additional access to new technology for physicians and patients in the evolving field of medical robotics. We are proud to welcome them as the first adopter of Liberty, and we are committed to supporting them every step of the way to ensure clinical and operational success.”
